LENZ Therapeutics Inc
NASDAQ:LENZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
There is not enough data to reliably calculate the intrinsic value for LENZ Therapeutics Inc.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What LENZ Therapeutics Does
LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. The company is headquartered in Solana Beach, California and currently employs 152 full-time employees. The company went IPO on 2021-06-25. The firm is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia.
- Headquarters
- United States of America US
- Employees
- 152
- IPO date
- Jun 25, 2021
Balance Sheet
Recent Events
Latest Earnings Call
LENZ is reshaping its U.S. commercial model around consumer marketing and telehealth, while announcing a CEO transition as it pursues VIZZ's growth.
Open the earnings call- EPS
- −$0.99
- Expected
- −$0.97
- Surprise
- −2.1%
- Stock, day of the call
- +8.7%
LENZ Therapeutics insiders are selling within their usual range
Past 12 months
Continue LENZ Research
Decided on LENZ Therapeutics? Get an email when LENZ reaches the price you’d buy at. Free with an account.